Pyxis Oncology
PYXS
80 hedge funds and large institutions have $93.1M invested in Pyxis Oncology in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 16 closing their positions.
9,133% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $18K
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
11% more funds holding
Funds holding: 72 → 80 (+8)
8.29% more ownership
Funds ownership: 39.48% → 47.77% (+8.3%)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less capital invested
Capital invested by funds: $97.8M → $93.1M (-$4.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.4M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$4.4M |
| 3 |
Millennium Management
New York
|
+$3.17M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.89M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$2.49M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.89M |
| 3 |
Goldman Sachs
New York
|
-$923K |
| 4 |
HF
HRT Financial
New York
|
-$592K |
| 5 |
Jane Street
New York
|
-$589K |
PYXS Hedge Fund Activity: Q2 2024 in Review
80 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q2 2024, worth a combined $93.1M — down 4.8% from $97.8M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PYXS positions and 16 closed out — a net gain of 9 holders — while 21 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $10.4M. The largest seller was Stempoint Capital, cutting an estimated $2.49M.
- 80 institutional investors held Pyxis Oncology (PYXS) as of Q2 2024, up from 72 in Q1 2024.
- Funds reported $93.1M of Pyxis Oncology stock for Q2 2024, down 4.8% quarter-over-quarter.
- 25 funds opened new Pyxis Oncology positions in Q2 2024 and 16 closed out, a net change of +9 holders.
- The largest Pyxis Oncology buyer in Q2 2024 was BlackRock, an estimated $10.4M added.
- The largest Pyxis Oncology seller in Q2 2024 was Stempoint Capital, an estimated $2.49M sold.
Based on aggregated 13F filings for Q2 2024.